Trade Receivables

9 Months Ended

Sep. 30, 2023

Product Sales

Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and RAPIVAB. At September 30, 2023 and December 31, 2022, receivables net of reserves related to sales of ORLADEYO were $51,837 and $41,508, respectively. A returns reserve related to sales of ORLADEYO of $124 was recorded as of September 30, 2023. No reserve or allowance amounts were recorded as of December 31, 2022. At September 30, 2023 and December 31, 2022, receivables related to sales of RAPIVAB were $132 and $823, respectively.

Collaborations

Receivables from collaborations were as follows (in thousands):


	September 30, 2023
	Billed		Unbilled		Total
U.S. Department of Health and Human Services, net	$	—	$	113	$	113
Royalty receivables from partners	1,564		—		1,564
Total receivables	$	1,564	$	113	$	1,677


	December 31, 2022
	Billed		Unbilled		Total
U.S. Department of Health and Human Services, net	$	7,218	$	284	$	7,502
Royalty receivables from partners	741		—		741
Other collaborations	—		25		25
Total receivables	$	7,959	$	309	$	8,268

As of September 30, 2023 and December 31, 2022, the Company maintained a reserve of $522 and $437, respectively, related to royalties associated with Green Cross.